Secukinumab in the treatment of psoriasis: patient selection and perspectives

• Main Authors: Yang EJ, Beck KM, Liao W
• Format: Article
• Language: English
• Published: Dove Medical Press 2018-10-01
• Series: Psoriasis : Targets and Therapy
• Subjects: secukinumab; IL-17 inhibitor; IL-17A; biologics; psoriasis; patient selection
• Online Access: https://www.dovepress.com/secukinumab-in-the-treatment-of-psoriasis-patient-selection-and-perspe-peer-reviewed-article-PTT

Eric J Yang,1,2 Kristen M Beck,1 Wilson Liao1 1Department of Dermatology, University of California San Francisco, San Francisco, CA, USA; 2Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA Abstract: Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly efficacious and well-tolerated. However, several biologic medications are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to choose biologics for specific patients. Important considerations in biologic selection include clinical efficacy, safety, cost, convenience, onset of action, and management of comorbid disease. This article aims to outline the key considerations in patient selection for the treatment of plaque psoriasis with secukinumab. Keywords: secukinumab, IL-17 inhibitor, IL-17A, biologics, psoriasis, patient selection